[Systolic and diastolic intervals in patients with hypertrophic obstructive cardiomyopathy before and after withdrawal of verapamil].
Mechanocardiographic investigations were carried out in a group of eight patients with hypertrophic obstructive cardiomyopathy (HOCM) who had been implanted a DDD pacemaker which allowed efficient therapy to be administered in the combination of metoprolol in the dose of 300 mg/day and verapamil in doses of 240-480 mg/day. The investigation was repeated one week after temporary withdrawal of verapamil. The control group consisted of six patients with idiopathic third-degree-complete AV block with implanted DDD pacemakers. Over the period of 24 hours before investigation, these patients received 300 mg of metoprolol. All the patients had the same heart rate (70 bpm) and a constant PQ interval (0.18 s). Statistical analysis of the obtained data revealed the following findings: 1. There was no difference between the control group and the group of HOCM patients treated with verapamil. 2. Withdrawal of verapamil in HOCM patients resulted in a significant prolongation of the 2-0 interval and shortening of the O-c interval recorded on apexcardiogram compared to the control group. In conclusion, verapamil affects LV diastolic parameters in patients with HOCM and the changes are compatible with the beneficial effects of verapamil. These changes may however result partly from increased left atrial pressure due to atrial poisoning with verapamil.
Jandík
J
J
Ustav patologické fyziologie LFUK, Hradec Králové.
Kvasnicka
J
J
Vokrouhlický
L
L
D002312:Cardiomyopathy, Hypertrophic / Q000188:drug therapy / Q000503:physiopathology* / Q000628:therapy; D003971:Diastole / Q000187:drug effects; D004562:Electrocardiography / Q000187:drug effects; D006801:Humans; D007702:Kinetocardiography / Q000187:drug effects; D009200:Myocardial Contraction / Q000187:drug effects; D010138:Pacemaker, Artificial; D013599:Systole / Q000187:drug effects; D014700:Verapamil / Q000627:therapeutic use*
D014700:Verapamil
Systolické a diastolické intervaly u nemocných s hypertrofickou obstruktivní kardiomyopatií pred vysazením a po vysazení verapamilu.